Literature DB >> 30822161

Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases.

Anne Caroline S Barbosa1, Ye Feng1,2, Chaohui Yu3, Min Huang4, Wen Xie1,5.   

Abstract

INTRODUCTION: Biotransformation is important in the metabolism of endobiotics and xenobiotics. This process comprises the activity of phase I and phase II enzymes. Estrogen sulfotransferase (SULT1E1 or EST) is a phase II conjugating enzyme that belongs to the family of cytosolic sulfotransferases. The expression of SULT1E1 can be detected in many tissues, including the liver. SULT1E1 catalyzes the transfer of a sulfate group from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to any available hydroxyl group in estrogenic molecules. The substrates of SULT1E1 include the endogenous and synthetic estrogens. Upon SULT1E1-mediated sulfation, the hydrosolubility of estrogens increases, preventing the binding between the sulfated estrogens and the estrogen receptor (ER). This sulfated state of the estrogens is not irreversible, as the steroid sulfatase (STS) can convert sulfoconjugated estrogens to free estrogens. The expression of SULT1E1 is inducible by several diseases that involve tissue inflammation, such as type 2 diabetes, sepsis, and ischemia-reperfusion injury. Areas covered: This systematic literature review aims to summarize the role of SULT1E1 in the metabolism of estrogenic drugs and xenobiotics, and the role of SULT1E1 in the pathogenesis of several diseases, including cancer, metabolic disease, sepsis, liver injury, and cystic fibrosis. Meanwhile, ablation or pharmacological inhibition of SULT1E1 can affect the outcomes of the aforementioned diseases. Expert opinion: In addition to its role in metabolizing estrogenic drugs, SULT1E1 is unexpectedly being unveiled as a mediator for the disease effect on estrogen metabolism and homeostasis. Meanwhile, because the expression and activity of SULT1E1 can affect the outcome of diseases, the same sulfotransferase and the reversing enzymes STS can be potential therapeutic targets to prevent or manage diseases. Accumulating evidence suggest that the physiological and pathophysiological effects of SULT1E1 can be estrogen-independent and it is necessary to elucidate what other possible substrates may be recognized by the enzyme. Moreover, human studies are paramount to confirm the human relevance of the animal studies.

Entities:  

Keywords:  Estrogen sulfotransferase; diseases; estrogen; estrogenic drugs; metabolism; phase II enzymes

Mesh:

Substances:

Year:  2019        PMID: 30822161      PMCID: PMC6428602          DOI: 10.1080/17425255.2019.1588884

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  110 in total

Review 1.  Sulfotransferases in the bioactivation of xenobiotics.

Authors:  H Glatt
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

Review 2.  The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.

Authors:  Ronald N Hines; D Gail McCarver
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

Review 3.  The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.

Authors:  D Gail McCarver; Ronald N Hines
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

4.  Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites.

Authors:  Ute M Kent; Danielle E Mills; Rajendram V Rajnarayanan; William L Alworth; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

5.  Crystal structure of the human estrogen sulfotransferase-PAPS complex: evidence for catalytic role of Ser137 in the sulfuryl transfer reaction.

Authors:  Lars C Pedersen; Evgeniy Petrotchenko; Sergei Shevtsov; Masahiko Negishi
Journal:  J Biol Chem       Date:  2002-03-07       Impact factor: 5.157

6.  Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs.

Authors:  M H Kester; S Bulduk; D Tibboel; W Meinl; H Glatt; C N Falany; M W Coughtrie; A Bergman; S H Safe; G G Kuiper; A G Schuur; A Brouwer; T J Visser
Journal:  Endocrinology       Date:  2000-05       Impact factor: 4.736

7.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

Authors: 
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

8.  Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites.

Authors:  M Park-Chung; A Malayev; R H Purdy; T T Gibbs; D H Farb
Journal:  Brain Res       Date:  1999-05-29       Impact factor: 3.252

9.  Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells.

Authors:  Y Otake; A L Nolan; U K Walle; T Walle
Journal:  J Steroid Biochem Mol Biol       Date:  2000 Jul-Aug       Impact factor: 4.292

10.  Substrate gating confers steroid specificity to estrogen sulfotransferase.

Authors:  E V Petrotchenko; M E Doerflein; Y Kakuta; L C Pedersen; M Negishi
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

View more
  10 in total

1.  Inhibition of Estrogen Sulfotransferase (SULT1E1/EST) Ameliorates Ischemic Acute Kidney Injury in Mice.

Authors:  Anne C Silva Barbosa; Dong Zhou; Yang Xie; You-Jin Choi; Hung-Chun Tung; Xinyun Chen; Meishu Xu; Robert B Gibbs; Samuel M Poloyac; Silvia Liu; Yanping Yu; Jianhua Luo; Youhua Liu; Wen Xie
Journal:  J Am Soc Nephrol       Date:  2020-05-18       Impact factor: 10.121

Review 2.  Sulfation pathways from red to green.

Authors:  Süleyman Günal; Rebecca Hardman; Stanislav Kopriva; Jonathan Wolf Mueller
Journal:  J Biol Chem       Date:  2019-07-02       Impact factor: 5.157

Review 3.  Filgotinib: A Clinical Pharmacology Review.

Authors:  Florence Namour; Kacey Anderson; Cara Nelson; Chantal Tasset
Journal:  Clin Pharmacokinet       Date:  2022-05-31       Impact factor: 5.577

4.  Hepatic Estrogen Sulfotransferase Distantly Sensitizes Mice to Hemorrhagic Shock-Induced Acute Lung Injury.

Authors:  Yang Xie; Anne Caroline S Barbosa; Meishu Xu; Patrick J Oberly; Songrong Ren; Robert B Gibbs; Samuel M Poloyac; Wen-Chao Song; Jie Fan; Wen Xie
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

5.  Estrogen Sulfotransferase is Highly Expressed in Vascular Endothelial Cells Overlying Atherosclerotic Plaques.

Authors:  Akira Sato; Hinako Watanabe; Miyuki Yamazaki; Eiko Sakurai; Keiichi Ebina
Journal:  Protein J       Date:  2022-01-20       Impact factor: 2.371

Review 6.  SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Authors:  Katsuhisa Kurogi; Mohammed I Rasool; Fatemah A Alherz; Amal A El Daibani; Ahsan F Bairam; Maryam S Abunnaja; Shin Yasuda; Lauren J Wilson; Ying Hui; Ming-Cheh Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-06-30       Impact factor: 4.936

7.  Pro-and anti-inflammatory effects of glucocorticoid Fluticasone on ovarian and immune functions in commercial-aged laying hens.

Authors:  Ali Hatefi; Ahmad Zare Shahneh; Zarbakht Ansari Pirsaraie; Ali Mohammad Alizadeh; Mohammad Pouya Atashnak; Reza Masoudi; Frederic Pio
Journal:  Sci Rep       Date:  2021-11-03       Impact factor: 4.379

8.  Acetaminophen Modulates the Expression of Steroidogenesis-Associated Genes and Estradiol Levels in Human Placental JEG-3 Cells.

Authors:  Kezia A Addo; Niharika Palakodety; Rebecca C Fry
Journal:  Toxicol Sci       Date:  2021-01-06       Impact factor: 4.849

9.  Sex-specific expression mechanism of hepatic estrogen inactivating enzyme and transporters in diabetic women.

Authors:  Muluneh Fashe; MyeongJin Yi; Tatsuya Sueyoshi; Masahiko Negishi
Journal:  Biochem Pharmacol       Date:  2021-06-23       Impact factor: 6.100

10.  DHEA Protects Human Cholangiocytes and Hepatocytes against Apoptosis and Oxidative Stress.

Authors:  Ewa Kilanczyk; Dagmara Ruminkiewicz; Jesus M Banales; Piotr Milkiewicz; Małgorzata Milkiewicz
Journal:  Cells       Date:  2022-03-18       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.